# First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors

> **NCT03758001** · PHASE1 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 38 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** IBI101
- **DRUG:** IBI101
- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT03758001
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-13
- **Primary completion:** 2023-02-16
- **Final completion:** 2023-02-16
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2023-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03758001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03758001, "First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03758001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*